Thank you to Alexandra Rojek, MD, of @uchicagocancer.bsky.social for participating in an interview which covered the evolving roles of CAR T-cell therapy and bispecifics in lymphoma! Check out our short on the topic which is live on onclive.com #oncology #hematology #CART #bispecifics

Treat #irAEs associated with #Bispecifics and T cell Engagers! Access the latest updates on #cytokine release syndrome and #immune effector cell-associated neurotoxicity during our free #webinar Dec. 17. Learn more and register: https://ow.ly/GByq50XgXSH

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial - Nature Medicine In the randomized phase 1b/2 Morpheus-Melanoma trial evaluating various neoadjuvant immune checkpoint inhibitor regimens in patients with resectable stage III melanoma, tobemstomig, an anti-PD-1/anti-LAG-3 bispecific antibody, showed the highest pathologic response rate with a better safety profile than the standard treatment approach of ipilimumab plus nivolumab.

💪#Power of #bispecifics in #cancer #patient #treatment?
✴️Anti-#PD1 x #LAG3 #bispecific had similar anti-#tumour #efficacy vs anti-#PD1/anti-#CTLA4 #combo but with better #safety #profile
⏲️Time to move #multispecifics vs #macrophages where #monos failed!
www.nature.com/articles/s41...

Dermatology’s next play: bispecifics that shut down OX40L and TNF - Biotech Industry Examiner Pairing a T-cell co-stimulatory brake with an inflammatory workhorse is an audacious idea. A handful of new readouts—plus a quietly advancing early-stage

One shot, two targets. OX40L–TNF bispecifics could reset HS care—if they beat HiSCR benchmarks and keep safety clean. Our FT-style breakdown: biology → data → payer math.
🔗 biotech.industryexaminer.com/ox40l-tnf-bi...

#Biotech #HS #Bispecifics #Dermatology

Novel Anti-Amyloid Drug Aims to Outperform Current Standards Engineered to cross blood-brain barrier and scavenge plaques more effectively

This is encouraging! An interim analysis of a Ph1b/2a study of an investigational anti-amyloid antibody drug shows promising results in #Alzheimers! And this drug is given by IV.

#AlzheimerDisease #Neurodegeneration #Antibodies #Bispecifics #Medicine

www.medpagetoday.com/meetingcover...

BIO 2025 is underway! Are you in Boston for the convention? If so, catch our panel buff.ly/mOU2AOu and connect with our experts on-site via the partnering system buff.ly/CBvenZt.

#BIO2025 #BIO #Bispecifics #Biologics #ProteinTherapeutics #ADCs #Biotech #Pharma

Will you be in Boston for #BIO2025? If so, be sure to catch our panel, "Beyond #Bispecifics and #ADCs: Conditionally Active #Biologics." buff.ly/mOU2AOu Connect with us on the partnering system or email contact@lumanity.com to meet.

#ProteinTherapeutics #Biotech #Pharma

Aleta’s Novel T Cell Engagers — SugarCone Biotech Aleta Bio recently announced that their scientists have created, characterized and validated novel classes of Immune Cell Engager therapeutics including T Cell Engagers (TCE) and CAR T Cell Engagers (...

omg it worked! #bispecifics #oncology #Tcells

www.sugarconebiotech.com/insights/ale... cc www.aletabio.com

Aleta’s Novel T Cell Engagers — SugarCone Biotech Aleta Bio recently announced that their scientists have created, characterized and validated novel classes of Immune Cell Engager therapeutics including T Cell Engagers (TCE) and CAR T Cell Engagers (...

Our most potent T cell bispecifics leverage natural T cell immunology to kill cancer cells ...

www.sugarconebiotech.com/insights/ale...

proprietary technology that works just as well with CAR T engager proteins

#aletabio #bispecifics #CARTcells

The #oncology dealmaking landscape is shifting. Pharma is moving to pan-cancer modalities such as #ADCs, #bispecifics and #radioligand therapies
www.nature.com/articles/d43...

Many readouts coming in the PD1/L x VEGF space. Let’s see if the data meets expectations and how approvals unfold. After several #FDA wins and compelling deals in #bispecifics, I’m eager to continue contributing to what’s coming next! What are your thoughts on the future of bispecifics in #oncology?

Fortunate to speak to colleagues in Brasil / Portuguese about #MM and #CART, #bispecifics. What a unique honor @mmkingt.bsky.social